Clinical Trial Update: A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma [Phase 1]

View source ↗

Summary

Pfizer's Phase I trial of the oral BRAF inhibitor LGX818 in adults with BRAF-mutant melanoma has completed and posted results. The study also includes patients …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Melanoma

Drugs mentioned

• LGX818 (encorafenib)

Snippet

Sponsor: Pfizer | Conditions: Melanoma and Metastatic Colorectal Cancer | Phase 1 | Status: COMPLETED | Results posted: 2024-10-28